Release date- 02102017 - EAGAN, MN - Biothera Pharmaceuticals, Inc. today announced that it will present new research at three upcoming healthcare conferences for Imprime PGG, Biothera's novel phase 2 cancer immunotherapy.
These presentations will provide data strengthening the scientific foundation for the use of Imprime PGG in combination with immune checkpoint inhibitors. The high profile late-breaking session of the AACR-NCI- EORTC will feature initial translational research from Biothera's ongoing phase 2 clinical study combining Imprime PGG and Merck's anti-PD-1 antibody, Keytruda, for the treatment of biomarker-positive patients with triple negative breast cancer or metastatic melanoma.
About Biothera Pharmaceuticals Inc.
Biothera Pharmaceuticals is a privately held biotechnology company developing Imprime PGG, a Phase 2 cancer immunotherapy that enhances the efficacy of anti-cancer immune response in combination with immune checkpoint inhibitor, tumor-targeting and anti-angiogenesis antibodies. Biothera Pharmaceuticals has clinical research agreements with Merck to evaluate Imprime PGG and KEYTRUDA in Phase 2 studies in advanced melanoma, metastatic triple negative breast cancer, and head and neck squamous cell cancer. This therapeutic combination also is the focus of a Big Ten Cancer Research Consortium Phase 1b/2 trial in patients with non-small cell lung cancer. Imprime PGG has demonstrated a favorable safety profile in more than 400 subjects and signals of activity in multiple combinations and tumor types.
(c) 2017 Electronic News Publishing -, source ENP Newswire